Table 1

Base case and plausible ranges of model inputs

Model inputBase caseRangeReference
Efficacy and safety outcome inputs 2–6 19–22
 Proportion of outcomes at 90 days in intravenous tPA group
 mRS 0–20.3250.258–0.392
 Death (mRS 6)0.1680.131–0.205
 sICH0.0580.035–0.095
 OR at 90 days
 mRS 0–22.0461.692–2.474
 Death (mRS 6)0.8710.684–1.109
 sICH0.9650.665–1.399
Probabilities inputs
 Proportion of patients received mechanical thrombectomy0.8610.839–0.883 2–6 19–22
 Proportion of patients arrived within 4.5 hours0.8540.839–0.869CNSR
 Recurrent rate of stroke (per patient year)CNSR
  mRS 0–20.10260.0961–0.1093
  mRS 3–50.14180.1303–0.1534
 Relative risk of stroke recurrence per life year1.031.02–1.04 23
 Death with recurrent stroke0.21010.1887–0.2316CNSR
 Age specific non-stroke death rate*0.0089–0.1653 25 26
 HR of non-stroke death for mRS 3–51.781.43–2.14 27
Cost inputs (2013 Chinese yuan renminbi)
  Additional costs of mechanical thrombectomy60 82152 314–70311EAST
  Additional costs of intravenous tPA treatment11 17910 555–11829CNSR, TIMS-CHINA
  Additional costs of sICH23742249–2504TIMS-CHINA
  One-time hospitalisation costsCNSR
  mRS 0–210 0559907–10205
  mRS 3–513 72913 428–14035
  mRS 611 12110 219–12081
  Annual posthospitalisation costsCNSR
  mRS 0–273857156–7619
  mRS 3–511 35010 730–11996
Utility inputs
  mRS 0–20.760.69–0.82 32
  mRS 3–50.210.17–0.26 32
  Death (mRS 6)00.00–0.00 32
  Recurrent stroke0.340.32–0.36 9
  sICH0.840.72–1.0 31
Discount rate inputs
  Costs0.030.03–0.08 29
  Outcomes0.03±20% 29
  • All costs were converted to 2013 Chinese yuan renminbi by using the medical care component of consumer price index; to convert CNY to US$, divide by 6.5.

  • *Age-specific non-stroke death rate: only the number of  63 years old (0.0089) and  93 years old (0.1653) are presented.

  • CNSR, China National Stroke Registry; EAST, Endovascular therapy for Acute ischaemic Stroke Trial; mRS, modified Rankin Scale; sICH, symptomatic intracerebral haemorrhage; TIMS-CHINA, Thrombolysis Implementation and Monitor of acute ischaemic Stroke in China; tPA, tissue plasminogen activator.